Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) + r-hFSH
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Reproductive Techniques, Assisted
Conditions
Reproductive Techniques, Assisted
Trial Timeline
Mar 1, 2005 → Apr 1, 2009
NCT ID
NCT01071200About Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) + r-hFSH
Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) + r-hFSH is a phase 3 stage product being developed by Merck for Reproductive Techniques, Assisted. The current trial status is terminated. This product is registered under clinical trial identifier NCT01071200. Target conditions include Reproductive Techniques, Assisted.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01071200 | Phase 3 | Terminated |
Competing Products
2 competing products in Reproductive Techniques, Assisted
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Durvalumab + Tremelimumab | AstraZeneca | Phase 2 | 52 |
| Gonal-f® + Pergoveris® + Pergoveris® + Recombinant human chorionic gonadotropin (r-hCG) | Merck | Phase 3 | 77 |